“My doctor has scheduled a prostate biopsy, but a friend told me that the biopsy could spread prostate cancer. Can this really happen?”
Quick Answer
A prostate biopsy does not normally cause prostate cancer to spread.
There have been rare reports of cancer cells growing along a biopsy needle tract, known as needle-tract seeding, but this complication is extraordinarily uncommon and is not considered a reason to avoid a medically indicated biopsy.
A prostate biopsy remains one of the main ways to confirm prostate cancer and determine its Grade Group when cancer is suspected.
Results commonly take several days to around one or two weeks, although the exact time depends on the pathology laboratory and whether additional tests are required.
Why Is a Prostate Biopsy Performed?
A prostate biopsy removes small samples of prostate tissue so that a pathologist can examine the cells under a microscope.
It may be recommended when findings such as PSA, prostate examination, MRI or other risk factors raise concern about clinically significant prostate cancer.
The biopsy can help determine:
- whether prostate cancer is present
- the Gleason score and Grade Group
- how much cancer is present in the sampled tissue
- how many biopsy cores contain cancer
- whether additional treatment or surveillance should be considered
A biopsy therefore provides information that PSA or MRI alone cannot fully provide.
You can read more about the diagnostic process in my prostate tests and diagnosis guide.
Can the Biopsy Needle Carry Cancer Cells Somewhere Else?
The concern is understandable because a biopsy needle passes into and then out of the prostate.
In theory, tumor cells can occasionally become displaced along the path of a biopsy needle.
This phenomenon is called needle-tract seeding.
However, documented cases after prostate biopsy are extremely rare.
A review of the published literature found only a small number of reported cases despite the enormous number of prostate biopsies performed worldwide.
Needle-tract seeding is biologically possible, but it is so uncommon that modern clinical practice does not consider it a reason to avoid an otherwise appropriate prostate biopsy.
Does Biopsy Send Prostate Cancer Into the Bloodstream?
There is no good evidence that routine prostate biopsy causes clinically important metastatic spread through the bloodstream.
Metastasis is a complex biological process.
For prostate cancer to establish a metastasis, cancer cells must do much more than simply become displaced. They must survive outside the original tumor, enter the circulation or lymphatic system, escape immune and mechanical barriers, reach another organ, survive there and establish new growth.
A biopsy needle passing through a tumor does not automatically trigger this process.
Does Biopsy Cause Prostate Cancer to Spread to the Bones?
No evidence supports the idea that a routine biopsy causes prostate cancer to spread to the bones.
Bone metastases occur because certain prostate cancers have already developed the biological ability to spread beyond the prostate.
If metastatic disease is discovered shortly after a biopsy, the cancer was almost certainly already present outside the prostate before the biopsy was performed.
Are Benign Tumors the Ones That Do Not Spread?
The old version of this page oversimplified this point.
Benign means a growth is not cancer.
Malignant means it is cancer and has the biological potential to invade surrounding tissue and spread.
Prostate adenocarcinoma is malignant by definition.
However, prostate cancers vary greatly in biological behavior.
Some Grade Group 1 cancers may grow so slowly that they can safely be monitored with active surveillance, while higher-grade cancers may have a greater risk of progression or metastasis.
This distinction is based on grade, stage, PSA and other findings—not simply whether a tumor has a “capsule.”
Is Biopsy Still Necessary in the MRI Era?
MRI has improved prostate cancer diagnosis considerably.
Multiparametric MRI can identify suspicious areas and help target biopsy samples toward lesions more likely to contain clinically significant cancer.
However, MRI by itself cannot always establish a definitive microscopic diagnosis or determine the Grade Group.
When biopsy is indicated, tissue remains important because the pathologist directly examines the prostate cells.
Transperineal vs Transrectal Biopsy
There are two common routes for prostate biopsy.
| Approach | How it is performed | Important consideration |
|---|---|---|
| Transperineal | The biopsy needle enters through the skin between the scrotum and anus. | Increasingly favored because infection risk is lower than with the transrectal route. |
| Transrectal | The needle passes through the rectal wall into the prostate. | Still used, but carries a higher infectious risk because the needle crosses rectal bacteria. |
Both approaches collect prostate tissue for pathology.
What Are the Real Risks of a Prostate Biopsy?
Rather than worrying primarily about cancer spread, patients should understand the complications that actually occur more often.
These include:
- blood in the urine
- blood in the semen
- rectal bleeding after transrectal biopsy
- infection
- fever or sepsis in uncommon cases
- temporary difficulty urinating
- acute urinary retention in some men
- temporary discomfort or pain
If you are taking aspirin or another antiplatelet or anticoagulant medicine, follow your biopsy team’s instructions rather than stopping or restarting it yourself.
See my guide to bleeding after prostate biopsy for more detail.
What Happens If Cancer Is Found?
A diagnosis of prostate cancer does not automatically mean immediate surgery or chemotherapy.
Treatment depends on the complete cancer risk profile.
Doctors consider factors such as:
- Grade Group
- PSA
- clinical stage
- MRI and other imaging
- number and extent of positive biopsy cores
- whether disease is confined to the prostate
- age and overall health
- life expectancy
- patient preferences
Depending on these findings, options may include active surveillance, radical prostatectomy, radiation therapy, hormone therapy or combinations of treatments.
Chemotherapy is not routinely given to every patient after prostate surgery.
How Long Do Prostate Biopsy Results Take?
“How long does it take to get a prostate biopsy result back?”
Many patients receive their pathology result within approximately one to two weeks.
Some laboratories may report results sooner, while others may take longer.
Turnaround time depends on laboratory workload, specimen processing and whether additional pathology work is needed.
Why Does a Biopsy Result Take Several Days?
The biopsy cores cannot simply be placed under a microscope immediately.
They must first go through several laboratory steps.
1. The tissue is preserved
The specimens are placed in fixative so that the tissue architecture and cells are preserved.
2. The cores are processed
The laboratory embeds the tissue in paraffin wax and cuts extremely thin sections.
3. The tissue is stained
Routine stains make the cells and tissue structures visible under the microscope.
4. A pathologist examines the slides
The pathologist determines whether cancer is present and, if so, evaluates its microscopic pattern.
5. Gleason Score and Grade Group Are Assigned
When prostate adenocarcinoma is diagnosed, the pathologist generally reports a Gleason score and corresponding Grade Group.
What Is Usually Included in the Pathology Report?
A prostate biopsy report may include:
- whether cancer was found
- which biopsy cores contain cancer
- Gleason score
- Grade Group
- percentage or length of each core involved by cancer
- percentage of Gleason pattern 4 when relevant
- other important pathological features
The number of positive cores and the amount of cancer within them can also help doctors assess overall disease risk.
Why Might the Result Take Longer?
Sometimes the routine microscopic appearance does not provide enough information for a confident diagnosis.
The pathologist may then request:
- additional tissue sections
- special stains
- immunohistochemistry
- review by another genitourinary pathologist
- additional molecular testing in selected situations
These additional steps can extend the reporting time.
Does Immunohistochemistry Happen on Every Biopsy?
No.
The old article suggested that cytology, immunohistochemistry and other specialized tests were routine for almost every prostate biopsy.
That is not correct.
Many prostate cancers can be diagnosed using standard histological examination.
Immunohistochemistry is used when it helps clarify a difficult or ambiguous finding.
Are Radioactive Substances Routinely Injected Into Biopsy Tissue?
No.
The old page described routine use of radioactively labeled substances to identify prostate cancer cells.
That is not a normal part of routine prostate biopsy pathology and should be removed.
Does a Delayed Result Mean Something Bad?
No.
A delayed report may occur because:
- the laboratory has a high workload
- additional slides are being prepared
- special staining is required
- a second pathology opinion is requested
- administrative processing takes longer
You cannot infer whether the biopsy is positive or negative from how many days the report takes.
When Should You Contact the Clinic?
Before leaving the biopsy appointment, ask:
- when results are normally available
- how you will receive them
- whether you need a follow-up appointment
- who to contact if the report is delayed
If the expected reporting date passes, it is reasonable to contact the urology clinic for an update.
When Should You Seek Urgent Care After the Biopsy?
- fever or shaking chills
- increasing or severe pain
- difficulty or inability to urinate
- heavy bleeding
- repeated large blood clots
- marked weakness or feeling seriously unwell
These complications matter much more clinically than the extremely rare possibility of needle-tract tumor seeding.
I understand why the idea that a biopsy might “disturb” a cancer can be frightening. However, the evidence does not support avoiding a medically indicated prostate biopsy because of fear that it will spread the cancer. Needle-tract seeding has been reported, but it is exceptionally rare. The much more practical questions are whether a biopsy is truly indicated, which biopsy approach is being used, what the infection and bleeding risks are, and how the pathology result will influence the next decision.